John P Sfakianos, MD Email John Sfakianos
- ASSISTANT PROFESSOR | Urology
- Hospital Affiliations
- Mount Sinai St. Luke's and Mount Sinai West
- Mount Sinai Queens
- The Mount Sinai Hospital
John Sfakianos, MD, is Assistant Professor of Urology and Urologic Oncology at the Icahn School of Medicine at Mount Sinai. His clinical focus includes treating patients with urothelial cancers of the upper urinary tract and bladder. He offers patients treatment options through his expertise in treating urologic conditions using open, laparoscopic and robotic techniques. He performs both robotic and open nephroureterectomies, partial cystectomies and cystectomies and forms urinary diversions including ileal conduits, continent catherizable pouches, and continent urinary diversions (ileal neobladder). His clinical interests and skills also include surgical treatment of patients with kidney, prostate, testicular and penile cancers.
Dr. Sfakianos is a firm believer in a multidisciplinary approach to cancer care. He works closely with his colleagues in medical oncology and radiation oncology to provide a customized, integrated and innovative approach to treatment of patients with urologic cancers. His research focuses on the approach to treating urothelial and prostate cancers in personalized medicine, including genomic analyses of tumors, to predict risk and response to therapy. In laboratory research, he is using mouse models in prostate and bladder cancer to identify novel treatments. Dr. Sfakianos has published over 20 research articles in peer-reviewed publications, written book chapters on urothelial carcinoma and is a reviewer for the Journal of Urology and Urologic Oncology.
Dr. Sfakianos received his medical degree from the School of Medicine and Biomedical Sciences at Buffalo and completed his internship and residency at the State University of New York at Downstate Medical Center. He went on to complete a fellowship in Urologic Oncology accredited by the Society of Urologic Oncology at the Memorial Sloan Kettering Cancer Center.
American Board of Urology
- Benign Prostatic Hyperplasia
- Bladder Cancer
- Kidney Cancer
- Kidney Stones
- Prostate Biopsy
- Prostate Cancer
- Prostate-Specific Antigen (PSA) Test
- Radical Cystectomy
- Robot-Assisted Urologic Procedures
- Robotic Kidney Surgery
- Robotic Prostate Surgery
- Testicular Cancer
MD, University at Buffalo
Internship, General Surgery
SUNY Downstate Medical Center
SUNY Downstate Medical Center
Fellowship, Urology Oncology
Memorial Sloan-Kettering Cancer Center
Winner, Chief's Debate
New York Academy of Medicine
Outstanding Pre -Urology Surgical Intern
SUNY Downstate Department of Surgery
Mohamed NE, Gilbert F, Lee CT, Sfakianos J, Knauer C, Mehrazin R, Badr H, Wittmann D, Downs T, Berry D, Given B, Wiklund P, Steineck G. Pursuing Quality in the Application of Bladder Cancer Quality of Life Research. Bladder Cancer; 2(2).
Galsky MD, Stensland K, Sfakianos JP, Mehrazin R, Diefenbach M, Mohamed N, Tsao CK, Boffetta P, Wiklund P, Oh WK, Mazumdar M, Ferket B. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2016 Jun;.
Sankin A, Tin AL, Mano R, Chevinsky M, Jakubowski C, Sfakianos JP, Cha EK, Yee A, Friedman FM, Sjoberg DD, Ehdaie B, Coleman J. Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes. Urology 2016 May;.
Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European Urology 2016 May;.
Mehrazin R, Tsao CK, Sfakianos J, Galsky MD. Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?. Urologic Oncology 2016 May; 34(5).
Husain FZ, Badani KK, Sfakianos JP, Mehrazin R. Emerging surgical treatments for renal cell carcinoma. Future Oncology (London, England) 2016 Apr; 12(7).
Paulucci DJ, Sfakianos JP, Yadav SS, Badani KK. BAP1 is overexpressed in black compared with white patients with Mx-M1 clear cell renal cell carcinoma: A report from the cancer genome atlas. Urologic Oncology 2016 Jun; 34(6).
Mullane SA, Bellmunt J. Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7. European Urology 2016 Feb;.
Liaw BC, Mehrazin R, Baker C, Sfakianos JP, Tsao CK. Management of Atypical Renal Cell Carcinomas. Current treatment options in oncology 2017 Sep; 18(10).
Beksac AT, Paulucci DJ, Blum KA, Yadav SS, Sfakianos JP, Badani KK. Heterogeneity in renal cell carcinoma. Urologic oncology 2017 Aug; 35(8).
Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Therapeutic advances in medical oncology 2017 Apr; 9(4).
Winoker JS, Paulucci DJ, Anastos H, Waingankar N, Abaza R, Eun DD, Bhandari A, Hemal AK, Sfakianos JP, Badani KK. Predicting Complications Following Robot-Assisted Partial Nephrectomy with the ACS NSQIP(®) Universal Surgical Risk Calculator. The Journal of urology 2017 Oct; 198(4).
Beksac AT, Paulucci DJ, Sfakianos JP, Reddy BN, Gin GE, Lerner SM, Badani KK. Trends in management of the small renal mass in renal transplant recipient candidates: A multi-institutional survey analysis. Urologic oncology 2017 Aug; 35(8).
Paulucci DJ, Sfakianos JP, Skanderup AJ, Kan K, Tsao CK, Galsky MD, Hakimi AA, Badani KK. Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma. Oncotarget 2017 Jan; 8(3).
Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD, Sankin AI, Sfakianos JP, Cha EK, Dalbagni G, Coleman JA. Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma. Urologic oncology 2017 Apr; 35(4).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Sfakianos during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- Pfizer Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.